Format

Send to

Choose Destination
Jpn J Clin Oncol. 2015 Jun;45(6):555-61. doi: 10.1093/jjco/hyv042. Epub 2015 Apr 2.

Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304).

Author information

1
Department of Endoprosthetic Surgery, Oita University, Oita.
2
JCOG Data Center, Center for Research Administration and Support, National Cancer Center, Tokyo.
3
Department of Orthopaedic Surgery, Osaka Medical Center, Osaka.
4
Department of Orthopaedic Surgery, National Cancer Center, Tokyo.
5
Department of Orthopaedic Surgery, Shizuoka Cancer Center, Shizuoka.
6
Department of Orthopaedic Surgery, Okayama University, Okayama.
7
Department of Orthopaedic Surgery, Kanagawa Cancer Center, Kanagawa.
8
Department of Orthopaedic Surgery, Kanazawa University, Ishikawa.
9
Department of Orthopaedic Surgery, Keio University, Tokyo.
10
Department of Orthopaedic Surgery, Niigata Cancer Center Hospital, Niigata.
11
Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan yiwamoto@ortho.med.kyushu-u.ac.jp.

Abstract

OBJECTIVE:

The efficacy of perioperative chemotherapy for soft tissue sarcomas is controversial and only a few prospective studies of pre-operative chemotherapy for soft tissue sarcomas in the extremities have been reported. We therefore carried out Phase II study of perioperative chemotherapy for patients with soft tissue sarcomas in the extremities.

METHODS:

Patients with Stage III non-round cell soft tissue sarcomas in the extremities were eligible. The patients were treated with pre-operative chemotherapy consisting doxorubicin 60 mg/m(2) and ifosfamide 10 g/m(2) for three courses. After the tumor resection, two additional courses of the same regimen were carried out.

RESULTS:

A total of 72 patients were enrolled and 70 patients were eligible. The median age of the patients was 49 years. The major pathological subtypes were synovial sarcoma in 20 and undifferentiated pleomorphic sarcoma in 17 patients. The protocol treatments were completed in 74% of the eligible cases. The 2 and 5-year progression-free survival rates were 75.7% (95% CI, 63.9-84.1%) and 63.8% (95% CI, 51.3-73.9%), respectively. The 5-year overall survival was 82.6% (95% CI, 71.3-89.7%). There was no treatment-related death. Grade 3 or 4 hematological toxicities (leukopenia and neutropenia) were observed in most of the patients.

CONCLUSIONS:

Although the toxicities of the regimen were significant, pre-operative chemotherapy followed by post-operative chemotherapy using doxorubicin and high-dose ifosfamide was feasible. The outcome of the trial for the patients with high-grade soft tissue sarcomas in the extremities was favorable, and this regimen is promising for further investigation. This trial was registered at the UMIN Clinical Trials Registry (www.umin.ac.jp/ctr/) as C000000096.

KEYWORDS:

chemotherapy; extremities; multicenter study; neoadjuvant therapy; sarcoma

PMID:
25838293
DOI:
10.1093/jjco/hyv042
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center